Psyched Wellness Ltd reported additional positive findings from the preclinical 14-day oral toxicity study with Amanita Muscaria (AME-1), which was performed in conjunction with an analysis of its impact on gut epithelial cells.
The company said the invivo study via oral supplementation with AME-1 focused on the potential bioactive effects on the immune receptors Toll-like Receptor-2 (TLR-2) and Dectin-1, both found in gut epithelial cells, which play an important role in defensive immune system mechanisms against pathogens.
The 14-day study resulted in a dose-dependent increase in TLR-2 expression, while Dectin-1 did not have any change in cell surface expression under the same study conditions, Psyched Wellness (CSE:PSYC, OTCQB:PSYCF) noted.
READ: Psyched Wellness launches new logo, branding and website ahead of its industry-first Amanita Muscaria mushroom product roll out
As a result, the marginal increase of up to two-fold in the TLR-2 study suggests AME-1 could be a potential bioactive agent with possible immune-priming effects, which may be due to its ability to increase cell surface plasma membrane concentration content of TLR-2.
“The importance of these initial invivo results indicate an innate immune-priming biological activity, potentially resulting in a more efficient response to an invading pathogen, thus promoting greater gut health and increased wellbeing of the individual,” said Brian Tancowny, scientific advisor for Psyched Wellness (CSE:PSYC, OTCQB:PSYCF), in a statement.
“While we plan to investigate this further, this is another key finding in understanding the effects of AME-1 and provides more evidence of the potential natural health benefits of the extract."
Psyched Wellness (CSE:PSYC, OTCQB:PSYCF) CEO Jeffrey Stevens added: “These results are very encouraging from an R&D perspective for building more knowledge on our proprietary extract, AME-1. These findings advance our conviction that we are just scratching the surface when it comes to the potential health benefits of AME-1 beyond our initial product pipeline, which we are continuing to examine in detail.”
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham